MedPath

Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

Phase 4
Completed
Conditions
Raynaud's Disease
Registration Number
NCT00048776
Lead Sponsor
Otsuka America Pharmaceutical
Brief Summary

Juvenile secondary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears. Children with secondary Raynaud's Phenomenon have an underlying condition such as systemic lupus, scleroderma, or mixed connective tissue disease. When children with secondary Raynaud's are exposed to chilly or cold conditions from weather, cold temperatures, or even holding cold items from the refrigerator, their fingers may become cold, numb, hurt, and/or turn purple or white. The investigational drug, Pletal(cilostazol), which has been approved for other conditions, inhibits the ability of one type of blood cell, platelets, to form blood clots, and also widens narrowed blood vessels. It has been used in a variety of other conditions in which blood flow is decreased. This study will test the safety and effectiveness Pletal(cilostazol) to lessen the severity of the symptoms and decrease the number of secondary Raynaud's episodes in juvenile patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
75
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (19)

Madera Family Medical Group

๐Ÿ‡บ๐Ÿ‡ธ

Madera, California, United States

Children's Hospital Boston

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

St. Louis University Health Sciences Center

๐Ÿ‡บ๐Ÿ‡ธ

St. Louis, Missouri, United States

New York Medical College

๐Ÿ‡บ๐Ÿ‡ธ

Valhalla, New York, United States

The Milton S. Hershey Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Hershey, Pennsylvania, United States

Jobst Vascular Center

๐Ÿ‡บ๐Ÿ‡ธ

Toledo, Ohio, United States

Monarch Research Associates

๐Ÿ‡บ๐Ÿ‡ธ

Norfolk, Virginia, United States

Medical University of South Carolina

๐Ÿ‡บ๐Ÿ‡ธ

Charleston, South Carolina, United States

Children's Hospital and Regional Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Seattle, Washington, United States

Altoona Center for Clinical Research

๐Ÿ‡บ๐Ÿ‡ธ

Duncansville, Pennsylvania, United States

Advanced Medical Clinical Therapeutics

๐Ÿ‡บ๐Ÿ‡ธ

Anchorage, Alaska, United States

Connecticut Children's Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Hartford, Connecticut, United States

LaRabida Children's Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Advanced Medical Research Institute

๐Ÿ‡บ๐Ÿ‡ธ

Fresno, California, United States

Children's Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Omaha, Nebraska, United States

SUNY Downstate Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Brooklyn, New York, United States

Asthma & Allergy Research Center

๐Ÿ‡บ๐Ÿ‡ธ

Newark, New Jersey, United States

Schneider Children's Hospital

๐Ÿ‡บ๐Ÿ‡ธ

New Hyde Park, New York, United States

Children's Hospital of Buffalo

๐Ÿ‡บ๐Ÿ‡ธ

Buffalo, New York, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath